Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib +/- Immunotherapy in Advanced Colorectal Cancer
NCT05372198Phase 2Unknown
- Sponsor
- Hubei Cancer Hospital
- Start
- Mar 2022
- Primary completion
- Jan 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in colorectal cancer (CRC), sponsored by Hubei Cancer Hospital. Status: unknown.
02
Drugs
surufatinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05372198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372198.